Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
Tóm tắt
The increasing prevalence of diabetes and its inadequate management results in a heavy burden of the disease for the patients, the health and the productive system and the overall community. Consequently, it is necessary to have new effective drugs to treat people with diabetes to decrease such burden. DPP-4 inhibitors can help to cope with this demand, but its usage is challenged by its apparent high cost. The aim of the current study was to compare a simulated cost-effectiveness ratio of metformin (MET) plus one drug of the DPP-4 inhibitors family, saxagliptin (SAXA) or sulfonylurea (SU) treatment during a 20-year period, from the perspective of the social security system, in a cohort of people with Type 2 diabetes (T2DM) who did not attain glycosylated hemoglobin treatment target values only with MET. A discrete event simulation model (Cardiff diabetes model) based on UKPDS 68 was used to simulate disease progression and to estimate the economic and health treatment consequences in people with T2DM. The clinical efficacy parameters for SAXA administration were obtained from the literature; local standard costs were considered for drug acquisition, adverse events (AEs), and micro/macrovascular complications. Costs were expressed in US dollars (2009) with an annual 3.5% discount and a 20-year time horizon. The SAXA + MET treated group had a lower number of non-fatal events than the SU + MET treated group. The model also predicted a lower number of fatal macrovascular events for the SAXA + MET group (149.6 vs. 152.8). The total cost of the SAXA + MET cohort was 15% higher than that of the SU + MET cohort. Treatment with SAXA + MET resulted in a higher number of quality-adjusted life years (QALYs) (9.54 vs. 9.32) and life-years gained (LYGs) (20.84 vs. 20.76) compared to those treated with SU + MET. The incremental cost per QALY and LYG gained was $7,374 and $20,490, respectively. According to the criteria proposed by the Commission on Macroeconomics and Health, the use of the combination SAXA + MET is highly cost-effective in Argentina.
Tài liệu tham khảo
International Diabetes Federation: IDF Diabetes Atlas. Fourth Edition edition. Brussels; 2009. Available at: . Accessed on May 4, 2011 http://www.eatlas.idf.org
Ferrante D, Linetzky B, Konfino J, King A, Virgolini M, Laspiur S: Encuesta Nacional de Factores de Riesgo 2009: evolución de la epidemia de enfermedades crónicas no transmisibles en Argentina. Estudio de corte transversal. Rev Argent Salud Pública 2011, 2: 34–41.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321: 405–412. 10.1136/bmj.321.7258.405
Ong KL, Cheung BMY, Wong LYF, Wat NM, Tan KC, Lam KS: Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol 2008, 18: 222–229. 10.1016/j.annepidem.2007.10.007
Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, Ilkova H, Ramachandran A, Aschner P, IDMPS Investigators: Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009, 32: 227–233.
Ringborg A, Cropet C, Jönsson B, Gagliardino JJ, Ramachandran A, Lindgren P: Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract 2009, 63: 997–1007. 10.1111/j.1742-1241.2009.02098.x
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: American Diabetes Association; European Association for Study of Diabetes: medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care 2009, 32: 193–203. 10.2337/dc08-9025
DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131: 281–303. 10.7326/0003-4819-131-4-199908170-00008
Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002, 287: 360–372. 10.1001/jama.287.3.360
Charpentier G: Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 2002, 18: S70-S76. 10.1002/dmrr.278
Riddle MC: Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005, 34: 77–98. 10.1016/j.ecl.2004.12.002
American Association of Clinical Endocrinologists: Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007,13(S1):3–68.
Barnard K, Cox ME, Green JB: Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2010, 3: 363–372.
Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H: Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008,10(Suppl 1):43–55.
Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007, 30: 1638–1646.
McEwan P, Peters JR, Bergenheim K, Currie CJ: Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006, 22: 121–129. 10.1185/030079906X80350
McEwan P, Bergenheim K, Yuan Y, Tetlow AP, Gordon JP: Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics 2010, 28: 665–674. 10.2165/11535350-000000000-00000
Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR: UK Prospective Diabetes Study (UKDPS) Group: A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004, 47: 1747–1759. 10.1007/s00125-004-1527-z
Ministerio de Salud de la Nación: Guía de Práctica Clínica Nacional sobre Prevención. Buenos Aires: Diagnóstico y Tratamiento de la Diabetes Mellitus Tipo 2 Para el Primer Nivel de Atención; 2009. Available from: accessed on January 10, 2013 http://www.msal.gov.ar/ent/images/stories/equipos-salud/pdf/gpc_prevencion-diagnostico-tratamiento-diabetes-mellitus-tipo-2.pdf;
Sociedad Argentina de Diabetes: Guía del tratamiento de la diabetes mellitus tipo 2. Rev Soc Arg de Diabetes 2010, 44: 358–384.
National Institute for Health and Clinical Excellence: Clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes (partial update). NICE; 2009. Available from: accessed on 20 December 2009 http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf;
Gagliardino JJ, en representación del Grupo IDMPS: Resultados del International Diabetes Management Practices Study (IDMPS) en la Argentina en DMT2 [abstract]. Rev Soc Argent de . Diabetes 2008, 42: 132.
Gagliardino JJ, on behalf of the IDMPS Group: Results of International Diabetes Management Practices Study (IDMPS) in Argentina. In 29th World Congress of Internal Medicine. Buenos Aires: Abstracts Book; 2008:50. Available from: http://www.smiba.org.ar/isim2008/Libro-Final-trab-pres.pdf
Gagliardino JJ, on behalf of the IDMPS Group: International Diabetes Management Practices Study (IDMPS): Results in T2DM. In 29th World Congress of Internal Medicine. Buenos Aires: Abstracts Book; 2008:63. Available from: http://www.smiba.org.ar/isim2008/Libro-Final-trab-pres.pdf
Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I: D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010, 64: 1619–1631. 10.1111/j.1742-1241.2010.02510.x
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998,352(9131):837–853.
Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24: 275–286.
Ahrén B, Foley JE, Ferrannini E, Matthews DR, Zinman B, Dejager S, Fonseca VA: Changes in prandial glucagon levels after 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Diabetes Care 2010, 33: 730–732. 10.2337/dc09-1867
White J: Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc 2009,49(Suppl 1):S30-S40. Review
Madsbad S: Lliraglutide effect and action in diabetes (LEAD TM) Trial. Expert Rev Endocrinol Metab 2009, 4: 119–129. 10.1586/17446651.4.2.119
Health Survey for England: Health Survey for England 2003- trends. Available from: accessed on 20 December 2009 http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/PublicationsAndStatistics/PublishedSurvey/HealthSurveyForEngland/HealthSurveyResults/DH_4098913;
Clarke P, Gray A, Legood R, Briggs A, Holman R: The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003, 20: 442–450. 10.1046/j.1464-5491.2003.00972.x
Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S: The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005, 8: 581–590. 10.1111/j.1524-4733.2005.00046.x
Sherwyn L, Schwartz MD: Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010, 8: 405–418. 10.1016/j.amjopharm.2010.10.003
Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33: 428–433. 10.2337/dc09-1499
Weisbrod BA: The Health Care Quadrilemma: an essay on technological change, insurance, quality of care and cost containment. J Econ Literat 1991, 29: 523–532.
Burner ST, Waldo DR: National health expenditure projections,1994–2005. Health Care Financ Rev 1995, 16: 221–242.
Eddy DM: Benefit language: criteria that will improve quality while reducing costs. JAMA 1996, 275: 650–657. 10.1001/jama.1996.03530320074047
Eddy DM: Investigational treatments: how strict should we be? JAMA 1997, 278: 179–185. 10.1001/jama.1997.03550030021009
Canadian Task Force on the Periodic Health Examination: The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979, 121: 1193–1254.
U.S. Preventive Services Task Force: Guide to Clinical Preventive Services. 2nd edition. Baltimore: Williams and Wilkins; 1996.
Sachs JD: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
Baltussen RMPM, Adam T, Tan-Torres Edejer T, Hutubessy RCW, Acharya A, Evans DB, Murray CJL: Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
World Development Indicators database: World Bank. 2011. Available from: . Accessed on April 15 http://data.worldbank.org/
Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M: Cost-effectiveness of saxagliptin (Onglyza(®)) in type 2 diabetes in Sweden. Prim Care Diabetes 2012, 6: 127–136. 10.1016/j.pcd.2011.09.003
Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P: Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig 2012, 32: 189–202. 10.2165/11597060-000000000-00000